When Is Perioperative Bridging Anticoagulation Necessary?
Most AFib patients on warfarin do not need bridging — BRIDGE showed no difference in thromboembolism and more bleeding with LMWH bridging. Reserve bridging for mechanical mitral valve, recent (<3 months) VTE or stroke, or very high-risk AFib (CHA2DS2-VASc ≥7 or prior stroke with rheumatic heart disease). For DOACs, bridging is not needed — simply hold per renal function.
Evidence review
Pivotal trials, effect sizes, and the populations they studied. PubMed identifiers link directly to the source.
BRIDGE (2015)
PMID 260958671,884 AFib patients undergoing elective procedures
No bridging non-inferior for arterial thromboembolism (0.4% vs 0.3%); major bleeding lower with no bridging (1.3% vs 3.2%).
PAUSE (2019)
PMID 313808913,007 AFib patients on DOAC undergoing elective procedures
Standardized DOAC hold (no bridging) — arterial thromboembolism 0.2–0.6%, major bleeding 0.9–1.8%. No bridging needed.
PERIOP 2 (2021)
PMID 341082291,471 mechanical valve or high-risk AFib on warfarin
Low-dose LMWH bridging did not reduce thromboembolism but increased minor bleeding. Even in mechanical aortic valves, bridging benefit is marginal.
Practical decision algorithm
| If | Then |
|---|---|
| AFib on warfarin, CHA2DS2-VASc ≤6, no prior stroke | Hold warfarin 5 days pre-op, resume 24 hours post-op. No bridging. |
| AFib on warfarin, CHA2DS2-VASc ≥7 or stroke in past 3 months | Consider LMWH bridging; individualize with hematology. |
| Mechanical mitral valve | Bridge with LMWH or UFH. Bileaflet mechanical aortic valve without additional stroke risk factors is usually considered lower thromboembolic risk — hold warfarin without bridging per 2020 ACC/AHA valvular heart disease guideline. |
| VTE within 3 months | Bridge. Delay elective surgery when possible until >3 months. |
| DOAC (any indication) | Hold per renal function: apixaban/rivaroxaban 24–48 h (low bleed risk procedure), 48 h standard, 72 h high bleed risk. Dabigatran longer if eGFR reduced. |
Guideline position
2017 ACC Expert Consensus Decision Pathway on periprocedural management of anticoagulation in NVAF: no parenteral bridging for low-to-moderate risk AFib on warfarin (CHA2DS2-VASc 1–6); consider bridging at high risk (CHA2DS2-VASc 7–9 or recent stroke/TIA/SE). DOACs do not require bridging per PAUSE and 2022 ACCP perioperative antithrombotic guideline. Mechanical mitral valves and very recent VTE remain indications.
Contraindications and cautions
- Active major bleeding
- Neurosurgery or spinal procedures with LMWH bridging (even low-dose)
- Severe renal impairment (dabigatran — extend hold)
- Heparin-induced thrombocytopenia history (use argatroban or bivalirudin if bridging needed)